Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n...
Saved in:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2019
|
| 在線閱讀: | https://doi.org/10.1038/s41371-019-0207-x https://www.nature.com/articles/s41371-019-0207-x.pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|